Dosing Study of Remifentanil for Smooth Removal of the Laryngeal Mask Airway (LMA)
Information source: Ajou University School of Medicine
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Drug Usage
Intervention: remifentanil (Drug); laryngeal mask airway (LMA) (Device)
Phase: Phase 4
Status: Completed
Sponsored by: Ajou University School of Medicine Official(s) and/or principal investigator(s):
Jong Yeop Kim, MD, Study Director, Affiliation: Ajou University School of Medicine
Summary
The investigators attempted to determine the optimal effect-site concentration of
remifentanil for smooth removal of the LMA from propofol anesthesia.
Clinical Details
Official title: Effect-site Concentration of Remifentanil for Smooth Removal of the LMA From Propofol Anesthesia
Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Primary outcome: smooth removal of LMA
Detailed description:
At the end of the surgery, propofol infusion was stopped and remifentanil was titrated to
predetermined (initial concentration 1. 0 ng/ml for the first patient). LMA removal was
performed when the patients opened their eyes and spontaneous respiration and adequate tidal
volume and ventilatory frequency were confirmed.
Eligibility
Minimum age: 18 Years.
Maximum age: 60 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- ASA I-II patients undergoing general anesthesia for short elective surgery (<1 hr)
Exclusion Criteria:
- G-E reflux
- obesity (BMI>30)
- anticipated difficult airway
Locations and Contacts
Ajou University School of Medicine, Suwon 443-721, Korea, Republic of
Additional Information
Starting date: October 2013
Last updated: October 13, 2014
|
